Regulatory T cells (Tregs) are a promising therapy for several immune-mediated conditions
but manufacturing a homogeneous and consistent product, especially one that includes
cryopreservation, has been challenging. Discarded pediatric thymuses are an excellent
source of therapeutic Tregs with advantages including cell quantity, homogeneity and
stability. Here we report systematic testing of activation reagents, cell culture media,
restimulation timing and cryopreservation to develop a Good Manufacturing Practice (GMP) …